Oncoinvent ASA (CHIX:ONCINO) Short Percentage of Float


CHIX:ONCINO Oncoinvent ASA CHIX:ONCINO
36 GF Score
Price kr1,039.91
GF Value kr20,159.96
! 4 Warning Signs
View Full Analysis

What is Oncoinvent ASA Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

CHIX:ONCINO vs VRTX, REGN, ALNY: Short Percentage of Float Comparison

For the Biotechnology subindustry, Oncoinvent ASA's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncoinvent ASA Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Oncoinvent ASA's Short Percentage of Float falls into.


CHIX:ONCINO
36GF Score
Oncoinvent ASA CHIX:ONCINO
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Oncoinvent ASA (CHIX:ONCINO) Overvalued in 2026?

Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued. The current stock price of kr1,039.91 is trading 94.8% below its estimated GF Value™ of kr20,159.96.

Key valuation signals for CHIX:ONCINO:

  • Short Percentage of Float:
  • GF Value™: kr20,159.96 vs. price of kr1,039.91 (94.8% below fair value)
  • GF Score™: 36/100 with 4 warning signs

No single metric tells the full story. See the CHIX:ONCINO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Oncoinvent ASA Business Description

Address Gullhaugveien 7, Oslo, NOR, 0484
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
36GF Score

Get the complete analysis for CHIX:ONCINO

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,039.91
Price
kr20,159.96
GF Value